BeyondSpring Revenue and Competitors

BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are currently advancing the development of our lead asset Plinabulin, a novel cancer therapeutic, in a global Phase 3 trial in non-small-cell lung cancer (NSCLC) and initiating a pivotal global Phase 3 trial in prevention of docetaxel-induced neutropenia. As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. Immune enhancing effects via dendritic cell maturation 2. Tumor cell apoptosis via activation of RAS-JNK pathway 3. Vascular disruptive effects Given Plinabulin's potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • Immuno-oncology, with immune checkpoint inhibitors in NSCLC • CNS malignancies including glioblastoma (GBM) • KRAS positive mutant cancers